Economic information and modeling report
Modeling overview
19 evidence topics · 15 sources
Summary
- AD109 has no published price, and no cost-effectiveness or budget impact analysis of AD109 was identified.
- Company market sizing: the prospectus estimates approximately 80 million people with OSA in the United States aged 30 to 69 years, from a study Apnimed commissioned from Clarivate, and approximately one billion worldwide (WHO). The published Apnimed- and Clarivate-authored estimate (Sönmez et al. 2025) is 83.7 million U.S. adults aged 20 years and older in 2024, with OSA defined as an AHI4 of 5 or more events/hr (52% mild, 30% moderate, 18% severe). The two sources state different age bands. The prospectus also cites approximately 3 million new diagnoses per year (Komodo claims), approximately 23 million unique patients with an OSA diagnosis active in the healthcare system from 2019 to 2024 (IQVIA claims), and approximately 10.5 million diagnosed but untreated people. The last figure comes from an Inspire-supported National Sleep Foundation survey of 1,015 adults with self-reported diagnosis, in which approximately 31% of those diagnosed were not receiving treatment.
- Company payer research reports that payers perceive PAP non-compliance at greater than 60%; Apnimed's planned health economics and outcomes research may include real-world analyses of adherence, healthcare utilization, functional outcomes, and nocturnal oxygenation.
- Published cost-effectiveness of OSA treatments: CPAP for moderate to severe OSA had an ICER of $15,915 per QALY gained over a lifetime horizon in a Markov model (Pietzsch et al. 2011), and ICERs of $3354 (third-party payer) and $314 (societal) per QALY gained (Ayas et al. 2006). In another analysis, CPAP cost $12,495 per DALY averted from the health care system perspective and was dominant from the societal perspective (Streatfeild et al. 2019). A meta-analysis of 15 studies (34 in the systematic review) found CPAP cost-effective against other treatments collectively, against no treatment, and against oral appliances, with low certainty (Sajith Kumar et al. 2025). Hypoglossal nerve stimulation increased lifetime costs by $42,953 with an ICER of $39,471/QALY in a 5-state Markov model (Pietzsch et al. 2015). Published obesity models include OSA as a modeled outcome or complication (ICER 2025; Hoog et al. 2025; Annemans et al. 2026).
- Payer coverage of OSA treatments: Medicare initially limits CPAP coverage to a 12-week period and continues it only for beneficiaries who benefit (NCD 240.4). CMS states that beneficiaries prescribed Zepbound for moderate to severe OSA in adults with obesity should continue to receive Medicare Part D coverage, subject to the plan's utilization management requirements. An Aetna prior authorization policy for tirzepatide in OSA sets an initial authorization of 6 months and a continuation of 12 months, with continuation requiring a positive response. ICER reports that coverage was easier to obtain when a comorbidity was on the FDA label.
Product-specific economic evaluation of AD109
No evidence found.
Company estimate: total addressable U.S. population
Apnimed- and Clarivate-authored U.S. prevalence estimate (AHI4 of 5 or more, adults aged 20 years and older)
“OSA was defined as having an AHI4 ≥ 5 events/hr.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 83.7 million adults (aged 20 years and older) were estimated to be living with OSA in the US in 2024, of whom 49,459,041 (59%) were males and 34,257,378 (41%) females.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The distribution of OSA severity was estimated to be 52% mild, 30% moderate, and 18% severe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“I.S. and A.V.D. are employees of Clarivate Analytics. K.S.Y., J.C., and J.Y. are employees of Apnimed, Inc.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company estimate: diagnosed, newly diagnosed, and diagnosed untreated U.S. populations
Source of the diagnosed untreated estimate: Inspire-supported National Sleep Foundation survey
Company launch population and target patient profile
“Initial target is ~10.5M diagnosed not on PAP” (opens the source at this quote in a new tab)
“New diagnosis rate >3M/year” (opens the source at this quote in a new tab)
“Diagnosed within the past 2 years” (opens the source at this quote in a new tab)
“Intolerant to PAP (refused or failed)” (opens the source at this quote in a new tab)
Company payer research and planned health economics and outcomes research
CPAP cost-effectiveness in a U.S. lifetime model
“A Markov model was created to compare costs and effectiveness of different diagnostic and therapeutic strategies over a 10-year interval and the expected lifetime of the patient. The primary measure of cost-effectiveness was incremental cost per quality-adjusted life year (QALY) gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For a patient with moderate-to-severe OSA, CPAP therapy has an incremental cost-effectiveness ratio (ICER) of $15,915 per QALY gained for the lifetime horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CPAP cost-effectiveness from third-party payer and societal perspectives, U.S. Medicare costs
“From a third-party payer or a societal perspective, CPAP therapy was more effective but more costly than no CPAP, with incremental cost-effectiveness ratios of $3354 or $314 per quality-adjusted life-year gained, respectively. The incremental cost-effectiveness ratio estimate was most dependent on viewpoint (varying more than 10-fold between societal and third-party payer perspectives) and choice of utility measurement method (varying more than 5-fold between the use of standard gamble and EuroQol 5D utility assessment values).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CPAP cost-effectiveness from health care system and societal perspectives, Australia
“From the health care system perspective, estimated cost of CPAP therapy to treat OSA was $12 495 per DALY averted while from a societal perspective the effect was dominant (-$10 688 per DALY averted) meaning it costs more not to treat the problem than to treat it.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of cost-utility studies of obstructive sleep apnea therapies
“Thirty-four studies were included in the systematic review, fifteen qualifying for meta-analysis. CPAP was cost-effective compared to other treatments, with a INBp of $13,024 (95%CI $6,813 to $19,236), and substantial heterogeneity (I2 = 97.48%). Compared to no treatment and oral appliances (OAs), CPAP showed cost-effective INB values of $30,834 ($21,325 to $40,343) and $2,708 ($645 to $4,771) respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CPAP is cost effective compared to all treatments collectively, as well as specifically to OAs and no treatment though with low certainty.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hypoglossal nerve stimulation cost-effectiveness from a U.S. payer perspective, STAR trial projection
“A 5-state Markov model was used to predict cardiovascular endpoints (myocardial infarction [MI], stroke, hypertension), motor vehicle collisions (MVC), mortality, quality-adjusted life years (QALYs), and costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were estimated to increase by $42,953, resulting in a lifetime ICER of $39,471/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: obstructive sleep apnea as a tracked outcome in the ICER obesity model
Tirzepatide: Lilly-funded U.S. obesity model with sleep apnea as a modeled complication
“Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The default analysis adopts a US commercial third‐party payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded by Eli Lilly and Company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: UK obesity model with obstructive sleep apnea remission and progression
“Key improvements over a previously published model were introduced, including modelling remission and progression of OSA, capturing realistic patterns of D&E discontinuation, incorporating HbA1c as a continuous cardiometabolic endpoint and transition to R-based implementation over VBA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote